Cardinal Health, Inc. (CAH)

US — Healthcare Sector
Peers: MCK  COR  HSIC  OMI  BDX  BAX  BEN 

Automate Your Wheel Strategy on CAH

With Tiblio's Option Bot, you can configure your own wheel strategy including CAH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CAH
  • Rev/Share 926.1917
  • Book/Share -7.9083
  • PB -13.4271
  • Debt/Equity -2.6048
  • CurrentRatio 0.9436
  • ROIC 0.1279

 

  • MktCap 39364997610.0
  • FreeCF/Share 10.1625
  • PFCF 16.1398
  • PE 25.4064
  • Debt/Assets 0.154
  • DivYield 0.0123
  • ROE -0.5014

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 2
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade CAH Wells Fargo Equal Weight Overweight -- $179 June 3, 2025
Upgrade CAH Jefferies Hold Buy $140 $150 Feb. 5, 2025
Upgrade CAH TD Cowen Hold Buy $130 $144 Jan. 8, 2025
Upgrade CAH Evercore ISI In-line Outperform -- $140 Jan. 7, 2025
Upgrade CAH BofA Securities Neutral Buy $132 $145 Jan. 6, 2025
Upgrade CAH Wells Fargo Underweight Equal Weight $101 $127 Dec. 13, 2024
Resumed CAH Mizuho -- Outperform -- $139 Dec. 4, 2024

News

Cardinal Health (CAH) Laps the Stock Market: Here's Why
CAH
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Neutral

In the closing of the recent trading day, Cardinal Health (CAH) stood at $164.93, denoting a +1.82% move from the preceding trading day.

Read More
image for news Cardinal Health (CAH) Laps the Stock Market: Here's Why
Cardinal Health (CAH) Stock Falls Amid Market Uptick: What Investors Need to Know
CAH
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Negative

In the most recent trading session, Cardinal Health (CAH) closed at $161.98, indicating a -1.47% shift from the previous trading day.

Read More
image for news Cardinal Health (CAH) Stock Falls Amid Market Uptick: What Investors Need to Know
Cardinal Health (CAH) is a Great Momentum Stock: Should You Buy?
CAH
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Does Cardinal Health (CAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Read More
image for news Cardinal Health (CAH) is a Great Momentum Stock: Should You Buy?
5 Must-Watch Stocks Favored by Brokers as 2H25 Begins
AN, ARCB, BGSF, CAH, CBRL
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Brokers are bullish on CBRL, BGSF, ARCB, CAH and AN as improving estimates and value metrics signal strength for 2H25.

Read More
image for news 5 Must-Watch Stocks Favored by Brokers as 2H25 Begins
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
CAH
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Read More
image for news Are Investors Undervaluing Cardinal Health (CAH) Right Now?
Wall Street Bulls Look Optimistic About Cardinal (CAH): Should You Buy?
CAH
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Read More
image for news Wall Street Bulls Look Optimistic About Cardinal (CAH): Should You Buy?
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
CAH
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Read More
image for news Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
Cardinal Health (CAH) is a Top-Ranked Value Stock: Should You Buy?
CAH
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Cardinal Health (CAH) is a Top-Ranked Value Stock: Should You Buy?
Cardinal Health (CAH) is a Top-Ranked Momentum Stock: Should You Buy?
CAH
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Cardinal Health (CAH) is a Top-Ranked Momentum Stock: Should You Buy?
Cardinal Health Analyst Flags Fading Scale Gap, Sees Rising Edge in Specialty Growth
CAH
Published: June 11, 2025 by: Benzinga
Sentiment: Positive

BofA Securities analyst Allen Lutz reiterated the Buy rating on Cardinal Health, Inc. CAH, raising the price forecast from $165 to $170.

Read More
image for news Cardinal Health Analyst Flags Fading Scale Gap, Sees Rising Edge in Specialty Growth
Cramer's Stop Trading: Cardinal Health
CAH
Published: June 10, 2025 by: CNBC Television
Sentiment: Neutral

Jim Cramer breaks down why he's keeping an eye on shares of Cardinal Health.

Read More
image for news Cramer's Stop Trading: Cardinal Health
MCK vs. CAH: Which Drug Distribution Giant Has the Healthier Outlook?
CAH, MCK
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive

Both McKesson and Cardinal Health dominate drug distribution, but which stock offers better growth and stability in 2025? Here we discuss which company has better long-term potential.

Read More
image for news MCK vs. CAH: Which Drug Distribution Giant Has the Healthier Outlook?
Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt
CAH, GOOG, GOOGL, PM
Published: May 26, 2025 by: MarketBeat
Sentiment: Neutral

Lately, the market has been delivering more plot twists to investors than a season of Severance. Solid tech earnings come in tandem with pulled guidance from public-facing companies like airlines and retailers.

Read More
image for news Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt
4 Dividend Aristocrats Are Absolutely Crushing the S&P 500 in 2025
ABT, CAH, ED, KO
Published: May 23, 2025 by: 24/7 Wall Street
Sentiment: Positive

Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.

Read More
image for news 4 Dividend Aristocrats Are Absolutely Crushing the S&P 500 in 2025
Cardinal (CAH) Upgraded to Buy: Here's Why
CAH
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive

Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news Cardinal (CAH) Upgraded to Buy: Here's Why
Should Value Investors Buy Cardinal Health (CAH) Stock?
CAH
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Read More
image for news Should Value Investors Buy Cardinal Health (CAH) Stock?
63 Top Dividend Growth Stocks For May 2025
ACN, ADP, AEP, CAH, CVX, LRCX, PEP, WMT
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral

I present 63 high-quality dividend growth stocks for investment for May 2025, categorized by yield: High (4%+), Medium (2.5-3.9%), and Low (

Read More
image for news 63 Top Dividend Growth Stocks For May 2025
Cardinal Health releases new report on the cell and gene therapy industry
CAH
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral

Analysis charts the emergence and future of advanced therapies DUBLIN, Ohio , May 7, 2025 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2025 Advanced Therapies Report: Revolutionizing patient care – the promise and potential of cell and gene therapies, providing insights into the evolving landscape of cell and gene therapies (CGTs). This inaugural report is based on a comprehensive survey of more than 100 healthcare providers as well as interviews with subject matter experts and a patient who received CAR T-cell therapy, all of whom provide valuable insights into the state of the CGT industry.

Read More
image for news Cardinal Health releases new report on the cell and gene therapy industry
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
CAH
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Read More
image for news Are Investors Undervaluing Cardinal Health (CAH) Right Now?
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
CAH
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
Cardinal Health, Inc. (CAH) Q3 2025 Earnings Call Transcript
CAH
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral

Cardinal Health, Inc. (NYSE:CAH ) Q3 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Allen Lutz - Bank of America Joanna Dynak - Evercore Eric Percher - Nephron Michael Cherny - Leerink Partners Kevin Caliendo - UBS George Hill - Deutsche Bank Eric Coldwell - Baird Erin Wright - Morgan Stanley Daniel Grosslight - Citi Charles Rhyee - TD Cowen Steve Baxter - Wells Fargo Brian Tanquilut - Jefferies Steven …

Read More
image for news Cardinal Health, Inc. (CAH) Q3 2025 Earnings Call Transcript
CAH Q3 Earnings Beat Estimates, '25 EPS View Raised, Stock Gains
CAH
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Cardinal Health's third-quarter fiscal 2025 results benefit from solid Medical and Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.

Read More
image for news CAH Q3 Earnings Beat Estimates, '25 EPS View Raised, Stock Gains
Cardinal (CAH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
CAH
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Cardinal (CAH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Cardinal Health (CAH) Beats Q3 Earnings Estimates
CAH
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Cardinal Health (CAH) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.08 per share a year ago.

Read More
image for news Cardinal Health (CAH) Beats Q3 Earnings Estimates
Cardinal Health lifts full-year profit forecast again on specialty medicine sales
CAH
Published: May 01, 2025 by: Reuters
Sentiment: Positive

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast for the fourth time, betting on strong demand for costly specialty medicines and branded drugs.

Read More
image for news Cardinal Health lifts full-year profit forecast again on specialty medicine sales
Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook
CAH
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral

Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expiration GAAP 1 operating earnings were $730 million; GAAP diluted EPS was $2.10 Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35 Fiscal year 2025 non-GAAP EPS guidance2 raised and narrowed to $8.05 to $8.15, from $7.85 to $8.00 GI Alliance announces expansion into urology specialty therapeutic area DUBLIN, Ohio , May 1, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter …

Read More
image for news Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
BAX, BDX, CAH, DXCM, SYK
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive

This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.

Read More
image for news MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
Can Sustained Product Demand Drive CAH Stock Before Q3 Earnings?
CAH
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Neutral

The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an uncertain macroeconomic environment.

Read More
image for news Can Sustained Product Demand Drive CAH Stock Before Q3 Earnings?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
CAH, VRTX
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Read More
image for news Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
CAH, THC
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Read More
image for news Why Investors Need to Take Advantage of These 2 Medical Stocks Now

About Cardinal Health, Inc. (CAH)

  • IPO Date 1983-08-04
  • Website https://www.cardinalhealth.com
  • Industry Medical - Distribution
  • CEO Jason M. Hollar
  • Employees 47922

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.